Solid-state variation of troglitazone drug substance by using a different recrystallization method
Related Experiment Video
Updated: Sep 20, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Nobuyuki Suzuki1, Ko Kasahara, Yoshiaki Watanabe
1Product Development Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan. nobuyu@shina.sankyo.co.jp
Abstract:
Rapid and slow crystallization methods (A and B) were applied for troglitazone, an equal mixture of four stereoisomers. Differences in the powder x-ray diffractometry patterns and hygroscopic patterns were observed among the samples crystallized by these methods, suggesting that troglitazone has solid-state variation. In this article, troglitazone recrystallized by method A was evaluated to clarify its structural characteristics and physical property. The crystal structure of predried troglitazone recrystallized by method A was proved to be a dihydrate. By drying, it changed reversibly to an anhydrate, which is the same structure as the RS/SR form, keeping the same enantiomer ratio. The solubility of the troglitazone by method A higher than that by method B at all enantiomer levels. But making the troglitazone amorphous equalized the enantiomeric solubilities of the substances by both methods as well as increased the intrinsic solubilities. Troglitazone by both methods was proved to be stable and retained the ratio of the stereoisomers.
More Related Videos
12:30Synthesis of a Thiol Building Block for the Crystallization of a Semiconducting Gyroidal Metal-sulfur Framework
Published on: April 9, 2018
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Related Concept Videos
In Vitro Drug Dissolution: Alternative Methods
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Recrystallization: Solid–Solution Equilibria
Drug Dissolution: Requirements and Profile Comparison
In Vitro Drug Dissolution: Compendial Testing Models II
Clinically Relevant Drug Product Specifications: Methods of Establishment